Glenmark Pharma gets China approval for RYALTRIS nasal spray to treat allergic rhinitis

RYALTRIS is a first-of-its-kind fixed-dose combination nasal spray that brings together an olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid) to treat the symptoms of allergic rhinitis. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,835.80, up by ₹20.75, or 1.14%, on the BSE.

Source link